Introduction to Meningococcal Vaccines

Overview of Meningococcal Disease

In the past decade, vaccines designed to prevent meningococcal disease have become widely available. This study evaluates the cost-effectiveness of implementing a universal meningitis vaccination program for college students. Meningococcal disease is caused by the Neisseria meningitidis bacteria, which has six strains responsible for infections in humans. Vaccination programs have effectively controlled infections from serogroups A, C, W, and Y.

Emergence of Serogroup B

Currently, serogroup B is the most prevalent form of meningococcal disease among humans, with young adults aged 16 to 23 being particularly susceptible. A new meningitis vaccine is now recommended for the prevention of serogroup B infections. However, the cost-benefit ratio of vaccinating against this strain remains uncertain.

Cost-Effectiveness Study Design

Research Methodology

Researchers from Johns Hopkins University School of Medicine conducted a cost-effectiveness analysis to assess the viability of a universal vaccination program aimed at preventing meningococcal disease. The study utilized a decision tree model to evaluate the financial implications of vaccinating college-aged students entering a university.

Study Parameters

The model focused on a hypothetical four-year college with 5,000 students, faculty, and staff, assuming uniform risk of infection with Neisseria meningitidis serotype B. The analysis initiated a universal vaccination program based on a suspected outbreak, defined as a single confirmed case of meningococcal disease. The objective was to compare the cost-effectiveness of universal vaccination against the current practice, where individuals decide on vaccination.

Health and Societal Perspectives

Cost Considerations

The analysis included both health sector and societal perspectives. Health sector costs encompassed direct medical expenses related to illness, such as hospitalization and vaccine costs. Societal costs accounted for productivity losses due to fatalities and disabilities stemming from meningococcal disease complications.

Quality-Adjusted Life Years (QALY)

To quantify health outcomes, the study employed the quality-adjusted life years (QALY) measure, which adjusts life expectancy based on quality of life. A widely accepted threshold of $150,000 per QALY was referenced for evaluating cost-effectiveness in the United States.

Findings on Vaccination Cost-Effectiveness

Conclusion of the Analysis

The findings indicated that a formal universal vaccination program for young adults is not cost-effective. The expense of vaccinating each student exceeds $300,000, and an outbreak vaccination program could surpass $2.5 million. The incremental costs were calculated at approximately $13.9 million per QALY from a health sector perspective and $13.8 million from a societal viewpoint, significantly exceeding the accepted threshold.

Low Incidence of Meningococcal Disease

Despite being prevalent in young adults, new cases of meningococcal disease remain low. Additionally, vaccine efficacy diminishes over time. Over a four-year duration, a universal vaccination program could reduce the incidence from 9.2 cases to 4.6 cases per 1,000 students on a mid-sized campus. With 100,000 vaccinated individuals, fewer than five cases would be prevented, limiting the health benefits of the meningitis vaccine.

Limitations of the Study

The study’s design did not account for students with heightened risks of meningococcal disease, which limits the generalizability of the results. It also remains uncertain whether the meningitis vaccine is effective for outbreak prevention.

Current Standard of Care

Final Recommendations

In summary, routine meningitis vaccination for young adults is not deemed a cost-effective strategy due to low incidence rates, limited vaccine efficacy, and high costs. Given the current willingness to pay and the price of the meningitis vaccine, the existing standard of care—allowing individuals to make personal vaccination choices—remains the most cost-effective approach.

References

– Leeds IL, Namasivayam V, Bamogo A, et al. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults. Am. J. Prev. Med. 2018.
– Johns Hopkins Medicine Newsroom. Study Suggests Universal Meningitis Vaccination Is Not Cost-Effective For College Students. The Johns Hopkins University. 2018.
– Centers for Disease Control and Prevention. Serogroup B Meningococcal (MenB) VIS. US Department of Health and Human Services. 2016.
– GlaxoSmithKline Inc. Product Monograph. Bexsero. 2018.
– Bush, LM. Schmidt CE, Perez MT. Meningococcal Disease. Merck Manual Professional Version. 2018.